Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 4Carcinoma, Hepatocellular 2Tuberous Sclerosis 1Recurrence 1Prostate Cancer Patients 1Neoplasms 1Lymphangioleiomyomatosis 1Glioma 1Glioblastoma 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × carbon-11 acetate × Clear all
NCT00813566 2022-04-27

Multi-Tracer PET Assessment of Primary Brain Tumors

University of Utah

Phase 1 Completed
11 enrolled
CNS

Brain Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡